What Is It, and Why Does It Matter?
Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase‑qvfc) are prescription medicines for adults with a muscle condition known as generalized myasthenia gravis (gMG). The FDA has expanded their use to include all adult patients with gMG regardless of subtype, meaning more people living with this condition may now be eligible for the therapy. Before, these medicines were approved only for adults with anti-AChR antibody-positive gMG.
gMG is a rare long-term autoimmune disease in which the immune system mistakenly attacks the connection between nerves and muscles, leading to muscle weakness and severe fatigue that can sometimes be life-threatening. Most patients (about 80%) have antibodies against a protein called AChR, while others may have different antibodies, such as MuSK (found in about 1%-10% of cases) or LRP4 (found in about 1%-5% of cases). These antibodies interfere with normal communication between nerves and muscles, leading to muscle weakness and fatigue. But around 10% of patients have no detectable antibodies at all and are known as "triple seronegative." These patients often have more severe disease and have had fewer treatment options.
Vyvgart and Vyvgart Hytrulo contain a lab-made antibody fragment that works by blocking a protein called FcRn. By blocking FcRn, Vyvgart lowers the level of harmful antibodies in the blood that are involved in gMG. Vyvgart is given intravenously (by IV), and another form of the same medicine, Vyvgart Hytrulo, is given as a shot under the skin, also called a subcutaneous (SC) injection.
Why Was It Approved?
The FDA's decision was based on a clinical trial showing that Vyvgart improved symptoms and daily functioning in people with all subtypes of gMG while maintaining a consistent and well-tolerated safety profile.
The phase 3 study evaluated Vyvgart in people with gMG who did not have detectable anti-AChR antibodies, including those with anti-MuSK, anti-LRP4, and triple seronegative disease. Those using Vyvgart had rapid and sustained improvements in symptoms affecting daily functions such as speaking, vision, swallowing, and physical activity. The study met its primary endpoint, with patients achieving significant improvement in measures of daily living activities (MG-ADL score) compared to a placebo at week four. Benefits were sustained across multiple treatment cycles and across all subtypes. Improvements in MG-ADL scores and muscle strength tests (QMG scores) were consistently observed.
Vyvgart was generally well tolerated, with a safety profile consistent with prior studies in anti-AChR antibody-positive patients. The most common side effects were respiratory tract infection, headache, and urinary tract infection. Reactions where the needle went in were also reported with the shot given under the skin (Vyvgart Hytrulo).
What Do I Need to Know?
Vyvgart IV is given once a week for four weeks. Each dose is infused over about an hour. Your health care provider will decide if and when you need more treatment cycles. If you miss an infusion, you can receive it within three days of the scheduled time. You will be monitored during the infusion and for an hour after it ends.
Vyvgart Hytrulo is given as a shot under the skin. For gMG, you receive it weekly for four weeks per treatment cycle. You will be monitored for at least 30 minutes after each injection. After proper training, you or a caregiver may give the dose at home. If you miss a dose, you may use it within three days of the scheduled time.
This medicine can increase your risk of infections. If you currently have an infection, wait to start or resume treatment until it clears. Watch for symptoms during therapy, and tell your health care provider right away if they happen.
Before each new cycle, make sure your routine vaccines are up to date. You will be monitored for infusion-related or allergic reactions during and after treatment. Do not use Vyvgart if you have a history of allergic reactions to products that contain efgartigimod alfa. Tell your health care provider if you are pregnant, planning pregnancy, or breastfeeding, as it is not known whether the medicine may harm a fetus or pass into breast milk.
Vyvgart may lower the levels of other medicines that bind to FcRn, such as immunoglobulin products or monoclonal antibodies. Your health care provider may monitor these medicines for reduced effect and consider other options if you need long‑term therapy. Be sure to share all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements, to avoid potential interactions.